EX-99.1 2 d301725dex991.htm PRESS RELEASE Press Release

Exhibit 99.1



Masimo Reports Fourth Quarter and Full Year 2011 Financial Results;

Provides 2012 Financial Guidance

Q4 2011 Highlights (compared to Q4 2010):



Total revenue, including royalties, rose 6% to $112.3 million.



Product revenue rose 12% to $104.7 million.



Shipped 34,400 Masimo SET® and Masimo rainbow® SET units.



Masimo rainbow revenue rose 16% to $9.8 million.



GAAP EPS was $0.23 versus $0.26 in the year-ago period. Excluding one-time items in Q4 2010, GAAP EPS declined 21% in Q4 2011, compared to adjusted EPS of $0.29 in Q4 2010.


Full Year 2011 Highlights (compared to 2010):



Total revenue, including royalties, rose 8% to $439.0 million.



Product revenue rose 14% to $406.5 million.



Shipped 148,200 Masimo SET® and Masimo rainbow® SET units, increasing worldwide installed base by 15%.



Masimo rainbow revenue rose 4% to $34.1 million. Excluding the 2010 U.S. military order, rainbow revenue rose 18%.



GAAP EPS was $1.05 versus $1.21 in 2010, which included a one-time net gain of $0.18. Excluding one-time items in 2010, GAAP EPS rose 2% in 2011 from $1.03.


Irvine, California, February 14, 2012 – Masimo (NASDAQ: MASI) today announced its financial results for the fourth quarter and year ended December 31, 2011.

Masimo’s total fourth quarter revenue, including royalties, rose 6% to $112.3 million, compared to $105.6 million for the fourth quarter of 2010. Fourth quarter 2011 product revenue rose 12% to $104.7 million, compared to $93.8 million for the fourth quarter of 2010. For the fourth quarter of 2011, the company’s worldwide end-user business grew 17% and represented 86% of product revenue. OEM sales, which represented the remaining 14% of product revenue, declined 12% in the fourth quarter of 2011, compared to the same period in 2010. Revenue from Masimo rainbow product sales rose 16% to $9.8 million in the fourth quarter, compared to $8.4 million for the fourth quarter of 2010.

Net income for the fourth quarter was $13.8 million, or $0.23 per diluted share, compared to reported net income of $16.1 million, or $0.26 per diluted share, in the fourth quarter of 2010. Excluding one-time expenses in the year-ago period, Masimo’s adjusted net income and adjusted earnings per share for the fourth quarter of 2010 were $17.5 million and $0.29, respectively.

For 2011, Masimo’s total revenue rose 8% to $439.0 million, compared to $405.4 million in 2010. The company’s product revenue rose 14% to $406.5 million, compared to $356.4 million in 2010. Revenue from Masimo rainbow products rose 4% to $34.1 million, compared to $32.9 million in 2010. Excluding the $4.0 million U.S. military order in 2010 that did not repeat in 2011, rainbow revenue grew by 18%. Royalty revenue declined from $49.0 million in 2010 to $32.5 million in 2011.

Masimo’s net income for 2011 was $63.7 million, or $1.05 per diluted share, compared to 2010 net income of $73.5 million, or $1.21 per diluted share, which included $0.18 from the net of a one-time gain related to $30.8 million in antitrust proceeds from Covidien and offset by $14.7 million in one-time expenses. Excluding one-time items in 2010, Masimo’s 2010 adjusted net income and adjusted earnings per share were $62.5 million and $1.03, respectively.

During the fourth quarter, the company shipped approximately 34,400 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, down 18% compared to approximately 41,800 in the same prior-year period. For 2011, Masimo shipped approximately 148,200 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, down 2% compared to approximately 153,200 in 2010. Masimo estimates its worldwide installed base as of December 31, 2011 to be 979,000 units, up 15% from 855,000 units as of January 1, 2011.

Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, “Masimo finished 2011 with a 12% rise in fourth quarter product revenue, including 17% growth in our direct business. Strong double-digit sales growth in our U.S. acute care channel and international business, as well as a 16% increase in rainbow revenue, drove our product revenue performance in the quarter. We also grew our worldwide installed base by 15%, expanding our global reach and demonstrating the continuing demand for our superior Masimo SET pulse oximetry and rainbow SET Pulse CO-Oximetry technology.”

As of December 31, 2011, cash and cash equivalents were $129.9 million, compared to $88.3 million as of January 1, 2011. During the fourth quarter, the company used approximately $36 million in cash to purchase approximately 1.8 million shares of its common stock under a stock repurchase program authorized by the Board of Directors in mid-2011.

2012 Financial Guidance

Masimo expects fiscal 2012 total revenue to be approximately $483 million, including product revenue of $455 million and royalty revenue of $28 million. Included within the 2012 product revenue guidance is a rainbow revenue expectation of $45 million. The company expects fiscal 2012 GAAP earnings per share to be $1.20. Each of the components of Masimo’s guidance set forth above is an estimate only and actual performance could differ.

Conference Call

Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. A live webcast of the conference call will be available online from the investor relations page of the company’s corporate website at www.masimo.com. The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers. The reservation code for both dial-in numbers is 42982286. After the live webcast, the call will be available on Masimo’s website through March 14, 2012. In addition, a telephonic replay of the call will be available through February 28, 2012. The replay dial-in numbers are (800) 585-8367 for domestic callers and +1 (855) 859-2056 for international callers. Please use reservation code 42982286

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo’s rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can also be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of “Improving Patient Outcomes and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies; demand for our technologies; and expectations for total revenue, royalty revenue and product revenue, including rainbow revenue, and GAAP earnings per share, for the full fiscal year 2012. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors’ assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

# # #


Investor Contact: Sheree Aronson

  Media Contact: Dana Banks

Vice President, Investor Relations, Masimo Corporation

  Manager, Public Relations, Masimo Corporation

(949) 297-7043

  (949) 297-7348



Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation.



(unaudited, in thousands)


     December 31,
    January 1,



Current assets


Cash and cash equivalents

   $ 129,882      $ 88,305   

Accounts receivable, net of allowance for doubtful accounts

     57,013        49,694   

Royalties receivable

     7,102        12,000   


     45,944        45,028   

Prepaid expenses

     6,424        4,535   

Prepaid income taxes

     2,986        3,352   

Deferred tax assets

     11,576        12,555   

Other current assets

     2,008        2,136   







Total current assets

     262,935        217,605   

Deferred cost of goods sold

     51,679        47,184   

Property and equipment, net

     15,239        15,951   

Intangible assets, net

     11,393        10,497   


     448        448   

Deferred tax assets

     16,766        12,560   

Other assets

     7,644        5,990   







Total assets

   $ 366,104      $ 310,235   









Current liabilities


Accounts payable

   $ 27,302      $ 22,150   

Accrued compensation

     19,717        21,074   

Accrued liabilities

     12,297        9,832   

Income taxes payable

     570        722   

Deferred revenue

     16,019        16,369   

Current portion of capital lease obligation

     48        50   







Total current liabilities

     75,953        70,197   

Deferred revenue

     984        1,554   

Capital lease obligation, less current portion

     74        122   

Other liabilities

     9,427        8,323   







Total liabilities

     86,438        80,196   



Masimo Corporation stockholders’ equity:


Common stock

     58        59   

Treasury stock

     (37,396     (1,209

Additional paid-in capital

     243,528        222,206   

Accumulated other comprehensive income

     1,274        925   

Retained earnings

     69,364        5,664   







Total Masimo Corporation stockholders’ equity

     276,828        227,645   

Noncontrolling interest

     2,838        2,394   







Total equity

     279,666        230,039   







Total liabilities and equity

   $ 366,104      $ 310,235   









(unaudited, in thousands, except per share information)


     Three Months Ended     Twelve Months Ended  
     December 31,
    January 1,
    December 31,
    January 1,




   $ 104,716      $ 93,775      $ 406,487      $ 356,422   


     7,625        11,799        32,501        48,985   













Total revenue

     112,341        105,574        438,988        405,407   

Cost of goods sold

     38,729        31,446        144,854        119,825   













Gross profit

     73,612        74,128        294,134        285,582   

Operating expenses:


Selling, general and administrative

     43,930        44,227        169,205        174,089   

Research and development

     9,619        8,312        38,412        36,000   

Antitrust litigation proceeds

     —          —          —          (30,728













Total operating expenses

     53,549        52,539        207,617        179,361   













Operating income

     20,063        21,589        86,517        106,221   

Non-operating income (expense)

     (468     154        14        1,348   













Income before provision for income taxes

     19,595        21,743        86,531        107,569   

Provision for income taxes

     5,429        5,112        22,478        34,164   













Net income including noncontrolling interests

     14,166        16,631        64,053        73,405   

Net (income) loss attributable to noncontrolling interests

     (346     (517     (353     125   













Net income attributable to Masimo Corporation

   $ 13,820      $ 16,114      $ 63,700      $ 73,530   













Net income per share attributable to Masimo Corporation stockholders:



   $ 0.23      $ 0.27      $ 1.07      $ 1.25   














   $ 0.23      $ 0.26      $ 1.05      $ 1.21   













Weighted average shares used in per share calculations:



     59,223        59,145        59,659        58,769   














     60,180        60,839        60,845        60,609   













Cash dividend declared per share

   $ —        $ 0.75      $ —        $ 2.75   













The following table presents the total share-based compensation expense (benefit) that is included in each functional line item of the consolidated statements of income (in thousands):


     Three Months Ended      Twelve Months Ended  
     December 31,
    January 1,
     December 31,
     January 1,

Cost of goods sold

   $ (36   $ 132       $ 383       $ 483   

Selling, general and administrative

     2,709        2,519         10,268         9,033   

Research and development

     836        765         3,025         2,787   














   $ 3,509      $ 3,416       $ 13,676       $ 12,303   















(unaudited, in thousands)


     Year ended
December 31,
    Year ended
January 1,

Cash flows from operating activities:


Net income including noncontrolling interests

   $ 64,053      $ 73,405   

Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:


Depreciation and amortization

     7,342        6,584   

Share-based compensation

     13,676        12,303   

Provision for doubtful accounts

     231        108   

Provision for obsolete inventory

     2,130        619   

Provision for warranty costs

     2,592        2,355   

Benefit from deferred income taxes

     (3,217     (2,231

Income tax benefit from exercise of stock options granted prior to January 1, 2006

     1,650        4,851   

Excess tax benefits from share-based compensation arrangements

     (67     (707

Changes in operating assets and liabilities:


Increase in accounts receivable

     (7,549     (10,905

(Increase) decrease in royalties receivable

     4,898        (500

Increase in inventories

     (3,046     (14,088

Increase in deferred cost of goods sold

     (4,526     (19,080

Increase in prepaid expenses

     (1,874     (743

(Increase) decrease in prepaid income taxes

     366        (1,648

Increase in other assets

     (1,502     (1,396

Increase in accounts payable

     5,159        5,474   

Increase (decrease) in accrued compensation

     (1,333     3,219   

Decrease in accrued liabilities

     (77     (2,281

Increase (decrease) in income taxes payable

     (89     940   

Increase (decrease) in deferred revenue

     (921     3,012   

Increase in other liabilities

     1,061        1,729   







Net cash provided by operating activities

     78,957        61,020   







Cash flows from investing activities:


Purchase of short-term investments

     —          (75,986

Proceeds from sale and maturities of short-term investments

     —          132,975   

Purchases of property and equipment

     (5,057     (9,561

Increase in intangible assets

     (2,451     (1,937







Net cash provided by (used in) investing activities

     (7,508     45,491   







Cash flows from financing activities:


Repayments on long-term debt

     (50     (60

Proceeds from issuance of common stock

     5,943        10,239   

Excess tax benefits from share-based compensation arrangements

     67        707   

Dividends paid

     —          (161,978

Repurchases of common stock

     (36,187     —     

Short swing profit recovery

     73        —     







Net cash used in financing activities

     (30,154     (151,092







Effect of foreign currency exchange rates on cash

     282        832   







Net increase (decrease) in cash and cash equivalents

     41,577        (43,749

Cash and cash equivalents at beginning of period

     88,305        132,054   







Cash and cash equivalents at end of period

   $ 129,882      $ 88,305